cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cytokinetics Inc
11 own
11 watching
Current Price
$43.12
$-0.13
(-0.3%)
logo-cytk
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,078.21M
52-Week High
52-Week High
55.8
52-Week Low
52-Week Low
29.67
Average Volume
Average Volume
0.41M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization4,078.21M
icon52-Week High55.8
icon52-Week Low29.67
iconAverage Volume0.41M
iconDividend Yield--
iconP/E Ratio--
What does the Cytokinetics Inc do?
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as well as other indications associated with muscle weakness; and with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, which is in Phase III clinical trial in patients with heart failure. Amgen Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and other countries; and Astellas Pharma Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil and related compounds. The company was founded in 1997 and is headquartered in South San Francisco, California.
Read More
How much money does Cytokinetics Inc make?
News & Events about Cytokinetics Inc.
Zolmax
9days ago
Cytokinetics (NASDAQ:CYTK Get Rating) had its price objective raised by stock analysts at The Goldman Sachs Group from $47.00 to $56.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical companys stock. The Goldman Sachs Groups ...
Globe Newswire
1month ago
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to review the New Drug ...
Globe Newswire
1month ago
Analysis from FORTITUDE-ALS Shows Predicted Survival Risk ScoreStrongly Correlated with Decline in ALSFRS-R Findings Suggest Inclusion Criteria for COURAGE-ALS Will Enrich forthe Enrollment of Faster Progressors SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, ...
Ticker Report
2 months ago
StockNews.com lowered shares of Cytokinetics (NASDAQ:CYTK Get Rating) from a hold rating to a sell rating in a research note released on Friday. Other equities analysts have also recently issued reports about the stock. Raymond James boosted their price objective on shares of Cytokinetics ...
Frequently Asked Questions
Frequently Asked Questions
What is Cytokinetics Inc share price today?
plus_minus_icon
Can Indians buy Cytokinetics Inc shares?
plus_minus_icon
How can I buy Cytokinetics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cytokinetics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cytokinetics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cytokinetics Inc?
plus_minus_icon
What is today’s market capitalisation of Cytokinetics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cytokinetics Inc?
plus_minus_icon
What percentage is Cytokinetics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cytokinetics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$43.12
$-0.13
(-0.3%)
logo-cytk
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$70.27
$-1.23 (-1.72 %)
Seres Therapeutics Inc
Seres Therapeutics Inc
$5.53
$0.02 (0.36 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$122.89
$-1.58 (-1.27 %)
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
$37.65
$-0.50 (-1.31 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$70.27
$-1.23 (-1.72 %)
Seres Therapeutics Inc
Seres Therapeutics Inc
$5.53
$0.02 (0.36 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$122.89
$-1.58 (-1.27 %)
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
$37.65
$-0.50 (-1.31 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00